Peptide Market Forecast & Key Players to Watch

The global peptide market is expected to grow at a compound annual growth rate (CAGR) of 7.9% over the next eight years, reaching a value of around USD 90.2 billion by 2033. With the general public’s increased focus on contemporary treatments, peptide therapies are reshaping the pharmaceutical landscape. Increasingly, peptide drugs are entering the market, supported by clinical trials and legislative backing. 

Currently, various peptide applications are in use, ranging from personalized wellness plans and vaccine development to treatments for chronic conditions. More than 100 peptide-based drugs are FDA-approved, revitalizing the pharmaceutical sector with promising results for chronic and life-threatening conditions. 

Trulicity and Ozempic are two key drugs dominating the diabetes and GLP-1 markets, with Ozempic alone recording sales of around $8.713 billion in 2020. The world is witnessing a surge in demand for these peptide-based drugs due to their strong effectiveness and favorable safety profiles. 

Key Entities of the Global Peptide Market

With increased collaboration between research institutes and pharmaceutical companies, FDA-approved peptide usage is steadily rising across global regions. Here are the key players behind this revolutionary medical landscape.

Thermo Fisher Scientific Inc.

With an annual revenue of around $40 billion, Thermo Fisher Scientific Inc. is advancing scientific research with its advanced technologies, offering a wide range of instruments, services, and products for drug development and therapeutic applications. By providing solvents such as dimethylformamide (DMF), N-methyl-2-pyrrolidone (NMP), and dichloromethane (DCM), it supports pharmaceutical companies in peptide synthesis. 

Its green alternative solvents like dimethyl sulfoxide (DMSO), anisole, and propyl acetate are promoting safer and more sustainable peptide manufacturing processes, helping companies meet regulatory requirements while minimizing environmental impact.

Merck KGA

This German company is one of the oldest entities in healthcare and life sciences, collaborating with pharmaceutical companies by offering advanced peptide synthesis instruments. With their macrocyclic peptide development, it is streamlining drug development processes and helping towards biological stability. 

In April 2025, it reached an agreement with the Austrian biotechnology firm Cyprumed aimed at transferring peptide therapies into oral formulations for obesity treatment.

Asahi Kasei Bioprocess America (AKBA)

AKBA is a big name in biotechnology research, offering services aimed at improving the effectiveness and safety of therapeutic products. In May 2025, its collaboration with PeptiSystems is expected to bring further innovations, addressing common challenges the peptide synthesis market is facing, such as high production costs, peptide degradation, and effective delivery.

Agilent Technologies Inc. (U.S.)

Headquartered in Santa Clara, California, this American company holds a strong position in the peptide synthesis market for its advanced instruments, research capabilities, and diagnostic solutions. With analytical instruments and supplies, lab testing, and lab automation services, it supports global companies in conducting cutting-edge life science research.

Agilent Technologies serves the pharmaceutical industry across innovative therapeutics, nutraceuticals, and vaccine development.

PolyPeptide Group

Founded in 2021, PolyPeptide Group is another key player serving pharmaceutical companies by offering peptide-based ingredients. In May 2024, it collaborated with Donaldson Company, Inc. to address common challenges in peptide purification. This collaboration aims to resolve important issues, particularly for long peptide sequences with complex physicochemical properties. 

Recently, in January 2025, it signed an agreement with Cytovance Biologics for mammalian- and microbial-expressed peptide drugs, marking a significant role in advancing therapeutics.

EUROAPI

As one of the world’s largest portfolios, EUROAPI is a major supplier of more than 200 pharmaceutical ingredients, reshaping the wellness industry. With Sanofi as a major shareholder, the company is meeting the rising demand for peptide-based drugs while trending as a top supplier of small-molecule APIs, particularly in European regions. In January 2025, it began collaborating with StrainChem on Liquid Phase Peptide Synthesis (SLiPPS) proprietary technology, aiming to overcome large-scale production challenges.

Novo Nordisk

This Denmark-based company is one of the leading pharmaceutical drug manufacturers, revolutionizing the diabetes landscape with its blockbuster drug called Ozempic (semaglutide). It was the first-ever oral GLP-1 drug approved in 2019 for marketing and sales, though it comes with some limitations.

Victoza is another non-insulin medication for patients with type 2 diabetes and heart issues. However, its sales decreased significantly in 2024 with the launch of generic GLP-1 drugs by Teva, its main competitor.

Teva 

Teva serves as a pioneer with its generic medicine portfolio, including innovative solutions such as liraglutide injection. It contributes to healthcare safety by providing effective glycemic control in adults and pediatric patients.

As one of the world’s top generic drug manufacturers, Teva plays an active role in offering patient-centered treatments with its innovative biopharmaceutical products.

Novartis

This Swiss multinational pharmaceutical corporation is a leader in the peptide synthesis market, with drugs such as Sandostatin, which is used to treat symptoms of carcinoid and peptide tumors. It collaborated with the Japanese biopharmaceutical company PeptiDream in May 2024 on peptide research and development, focusing on macrocyclic peptides. It is continuing to expand its drug pipeline in the coming years.

AstraZeneca

AstraZeneca is another pharmaceutical company and a key market player in peptide-based treatments. It serves breast and prostate cancer patients with therapeutic peptides in the form of the drug Zoladex. 

Soon, it is expected to lead the market by launching macrocyclic peptides following its collaboration with Syneron Bio in March 2025. These peptides will help modulate protein–protein interactions to treat various diseases, including autoimmune disorders.

What Future Holds for Peptide Sellers?

Currently, the biotechnology industry is witnessing innovative peptide-based technologies with heavy investment in R&D, aiming to overcome challenges in areas such as peptide degradation, effective delivery, and long-term biochemical impact.

By providing risk-free alternatives to biological processes, peptide drugs are trusted for managing a wide range of chronic illnesses, including cancer and HIV. Anti-aging compounds such as Matrixyl™ and Argireline™ are reshaping the cosmetics industry with rising demand for collagen stimulation.

Innovative approaches such as the automation of SPPS, Molecular Hiving™ technology, and Chemo-Enzymatic Peptide Synthesis (CEPS) are helping overcome challenges in industrial-scale production, boosting the peptide synthesis market in the coming years.

With a growing emphasis on sustainable synthetic approaches, the peptide market is expected to evolve, ensuring easier access to peptide therapies, including personalized wellness programs in the years ahead.